Trials / Completed
CompletedNCT02029157
A Randomized Double-blind, Placebo-controlled Japanese Phase III Trial of ARQ 197 in Hepatocellular Carcinoma (HCC)
A Phase III Randomized Double-blind, Placebo-controlled Trial of ARQ 197 in Subjects With c-MET Diagnostic-high Inoperable Hepatocellular Carcinoma (HCC) Treated With One Prior Sorafenib Therapy
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 386 (actual)
- Sponsor
- Kyowa Kirin Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The present clinical trial is aiming to evaluate efficacy of ARQ 197 in patients with hepatocellular carcinoma (HCC), who were resistant or intolerable to one systemic chemotherapy regimen including sorafenib.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ARQ197 | |
| DRUG | Placebo |
Timeline
- Start date
- 2014-01-01
- Primary completion
- 2017-08-01
- Completion
- 2017-08-01
- First posted
- 2014-01-07
- Last updated
- 2017-10-09
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT02029157. Inclusion in this directory is not an endorsement.